Open Access<p>Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice</p>
Author(s) -
Jiwoo Lee,
Yun Kyung Cho,
Hwi Seung Kim,
Chang Hee Jung,
JoongYeol Park,
Woo Je Lee
Publication year - 2019
Publication title -
diabetes, metabolic syndrome and obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.853
H-Index - 43
ISSN - 1178-7007
DOI - 10.2147/dmso.s231272
Subject(s) - dulaglutide , type 2 diabetes , medicine , clinical practice , insulin , diabetes mellitus , endocrinology , exenatide , family medicine
For patients with type 2 diabetes (T2DM) who remain above their glycemic target on insulin therapy, a combination of insulin and a glucagon-like peptide 1 receptor agonist has been recommended. However, few studies have been conducted to determine the clinical efficacy and parameters affecting the response to this combination in a real-world setting. This study aimed to investigate the clinical efficacy and parameters affecting the glycemic response to dulaglutide as an add-on to insulin therapy for T2DM in a real-world clinical setting.